<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03416933</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A00469-46</org_study_id>
    <nct_id>NCT03416933</nct_id>
  </id_info>
  <brief_title>Therapeutic Drug Monitoring of BRAF-mutated Advanced Melanoma</brief_title>
  <acronym>OPTIMEL</acronym>
  <official_title>Therapeutic Drug Monitoring of Kinase Inhibitors and Study of Circulating Tumor DNA in Patients With Mutated BRAF Metastatic Cutaneous Melanoma and Treated With Anti-BRAF and Anti-MEK Kinase Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de Lorraine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Cancérologie de Lorraine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BRAF V600-mutant metastatic melanoma are commonly treated using a combination of anti-BRAF
      and anti-MEK tyrosine kinase inhibitors (TKIs). The OPTIMEL trial aims to study the interest
      of therapeutic drug monitoring (TDM) of TKIs and circulating tumor DNA (ctDNA) detected in
      plasma of patients with metastatic melanoma for disease monitoring. 35 patients with
      metastatic melanoma and treated with dabrafenib and trametinib will be enrolled in this
      trial. Blood samples will be collected for the determination of TKIs concentration and ctDNA
      detection.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Link between the presence of circulating tumor DNA and plasma concentrations of kinase inhibitors n patient with advanced BRAF(V600) mutated melanoma</measure>
    <time_frame>1 day</time_frame>
    <description>ctDNA in patient with advanced BRAF(V600) mutated melanoma is estimated by the ratio of the Ct of the sample to the control. Plasma concentrations of anti-BRAF and anti-MEK tyrosine kinase inhibitors are expressed in μg / mL</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Melanoma (Skin)</condition>
  <arm_group>
    <arm_group_label>Biological</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>2x10 ml of patient peripherical blood will be collected at D0, D15, D30, D90, D180, D270 and with progression or at the end of the follow-up at the 12th month.</description>
    <arm_group_label>Biological</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women 18 years of age and older

          -  Histologic proven advanced skin melanoma (Stage IV or stage IIIc inoperable) with BRAF
             V600 mutation

          -  Patient who will treated with combined kinase inhibitors (dabrafenib + trametinib).

          -  Patient able to stand a blood collection of 20 mL

          -  Ability to provide an informed written consent form

          -  Patient must be affiliated to a social security system

          -  Patient's legal capacity to consent to study participation and to understand and
             comply with the requirements of the study.

        Exclusion Criteria:

          -  Patient with mucosal melanoma

          -  Patient with non-metastatic skin melanoma (All stages except stage IV and stage III C
             inoperable)

          -  Patient with another synchronous cancer, or within 3 years

          -  Patient with a contraindication to blood collection of 20 mL

          -  Patient deprived of liberty or under supervision

          -  Patient unable to receive kinase inhibitor therapy

          -  Patient treated with another combined kinase inhibitors than dabrafenib and trametinib

          -  Pregnant or breastfeeding women

          -  Patient (man or woman) of childbearing age who does not agree to use of contraceptive
             methods validated during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geoffrois Lionnel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de Lorraine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MERLIN JEAN LOUIS, PharmaD</last_name>
    <phone>+33 3 83 59 83 07</phone>
    <email>jl.merlin@nancy.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>FERNANDES LAURINDA</last_name>
    <phone>+33 3 83 59 84 87</phone>
    <email>l.fernandes@nancy.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital de Mercy</name>
      <address>
        <city>Ars-Laquenexy</city>
        <zip>57 245</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Truchetet François, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Muller Philippe Co-, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54 511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Granel-Brocard Florence, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Schmutz Jean-Luc, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine (ICL)</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Geoffrois Lionnel, MD</last_name>
      <email>l.geoffrois@nancy.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>Harlé Alexandre, PharmaD</last_name>
      <email>a.harle@nancy.unicancer.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2018</study_first_submitted>
  <study_first_submitted_qc>January 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2018</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ctDNA</keyword>
  <keyword>MAPK inhibition</keyword>
  <keyword>BRAF(V600) mutated</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

